Frozen Assets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Frozen Assets
Even when all is well at the facility, one must expect the worst while braving the elements.


Pharmaceutical Technology
Volume 36, Issue 11, pp. 16

Snow luck


Control, a senior compliance officer
"It was a snowy day," began our GMP Agent-In-Place. "The driver of the semitruck that was carrying our products from one of our distribution centers to another saw the truck skid ahead of him and slammed on the brakes. As a result, our truck jackknifed—hard enough to slice a hole in the trailer. The driver was okay, but due to the impact and the temperatures, the product was damaged. We ended up rejecting the $2.5-million worth of product that the truck contained."

Pig parts

"We were an old-line drugmaker," our GMP Agent-In-Place explained. "We still made some of our drugs from animal parts. One of the parts we used was the pork pituitary gland—it is a small gland within the skull of the pig, and we contracted with several large meatpacking companies to collect the gland for our company. It is not lucrative on the part of the meatpacking company because it requires the use of a specialized head-splitting device to cut the pig skull apart in order to collect the gland. Because only a few meatpackers had the device, we could not readily change our suppliers. When I asked about this, I learned that many of the head splitters were originally purchased by our company in the past and given to the meatpackers for use."

Maintenance issues

"We've had to deal with a recurring problem," said our GMP Agent-In-Place. "Some of our specialized lyophilization stoppers were not set properly on the vial and would tip off when the vial was moved to the lyophilizer, thereby losing the product within. When the problem became bad enough, we would call in the mechanic. Each time, the mechanic would fix the problem with the stopper setter. After a couple of fixes, we decided to see if we could prevent these occurrences, and as part of our investigation, we read the mechanic's notes. The notes said that the vacuum system used to set the stoppers was not releasing vacuum fast enough, and so the stopper would not be set properly. We ultimately corrected this with routine maintenance on the vacuum valves to prevent further loss of product. The maintenance period now occurs every quarter-year."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here